MIAMI, Sept. 21, 2015—Global Stem Cells Group, in collaboration with medical software company Datamed SA Chile, has announced the plans to launch StemData, the first cloud-based electronic medical record system specifically designed for regenerative medicine practitioners.
The new StemData system will come programmed with the latest point of care regenerative medicine protocols and follow-up procedures to make it easy for stem cell practitioners to document patient progress and gather important data to establish the safety and efficacy of stem cell treatments in an doctor’s office environment. The system app will be marketed exclusively through Global Stem Cells Group and will be provided free of charge to affiliate physicians in the new Stem Cell Center network.

The cloud-based, server-less StemData solution will be accessible via web, iPad, iPhone, Google Glass and Apple Watch. Global Stem Cells Group and Datamed have utilized the development of the latest electronic medical record (EMR) systems to bring intelligent EMR technology to regenerative medicine specialists.
The StemData app will help regenerative medicine physicians increase efficiencies in their medical practices while improving both treatment and business outcomes. The app will intuitively adapt to each individual practitioner’s unique practice preferences.
To learn more, visit the Global Stem Cells Group website, email bnovas(at)regenestem(dot)com, or call 305-224-1858.
About the Global Stem Cells Group:
Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.
Global Stem Cells Group’s corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCG’s six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.

Global Stem Cells Group has announce a new alliance with Santiago, Chile-based Cellus, a stem cell company dedicated to research, development and commercialization of therapeutic services and custom biotech products in regenerative medicine

MIAMI, FLA. (PRWEB) SEPTEMBER 28, 2015

Global Stem Cells Group has announced a new strategic alliance with Cellus to promote clinical research, physician training and patient treatment in Chile. Based in Santiago, Chile, Cellus is a stem cell company and full GMP lab dedicated to research, development and commercialization of therapeutic services and custom biotech products in the field of regenerative medicine.

Cellus’s state of the art medical facility, located at the Santiago Marriot, includes conference rooms with views to its cell culture lab and a full, cutting edge operating room for performing stem cell procedures. Cellus is managed by a multi-disciplinary team with extensive clinical experience and biopharmaceutical production, operating under the highest standards and international requirements for quality and safety. Cellus is continuously working to develop effective and innovative regenerative medicine solutions using autologous cellular therapies and biological products obtained from and administered to each individual patient.

“We are very pleased about our new alliance with Global Stem Cells Group,” says Cellus Commercial Manager Carlos Girardi. “We plan to leverage this alliance to further our clinical research, and to boost physician training here in Chile.

“This is a great opportunity to prove how valuable a collaboration between two international stem cell forces like Cellus and GSCG can be.”

Global Stem Cells Group, Chile CEO Enrique Testart agrees, adding that the new collaboration between the two companies will help GSCG establish itself as the leader in regenerative medicine therapies in Chile.

“Both Cellus and Global Stem Cells Group bring extraordinary insight, knowledge and experience in stem cell medicine to the table, and together we can accomplish great things,” Testart says. “I’m very excited to work with the excellent team at Cellus.”

The collaboration is part of Global Stem Cells Group’s push to highlight Chile’s appeal as a destination for patients seeking stem cell therapies for a variety of conditions, and as part of its ongoing commitment to expand the reach of stem cell treatments throughout Latin America.

To learn more, visit the Global Stem Cells Group website, email bnovas(at)regenestem(dot)com, or call 305-224-1858.

About the Global Stem Cells Group:

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

Global Stem Cells Group’s corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCG’s six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.

About Cellus:

Cellus is dedicated to research, development and commercialization of therapeutic services and custom biotech products in the field of regenerative medicine. Their multidisciplinary team of stem cell experts focus on the prevention and reversal of impairment in the skin of patients with traumatic injuries, skin diseases or symptoms of aging.

Their state-of-the-art facility in Santiago features a full laboratory and showcases the company’s extensive clinical expertise and biopharmaceutical production capabilities.

###

Global Stem Cells Group announces a new alliance with Santiago, Chile-based VidaCel Laboratories, Latin America’s oldest and largest cryopreserved umbilical cord blood bank.

MIAMI (PRWEB) SEPTEMBER 25, 2015

Global Stem Cells Group has announced a new collaboration with Santiago, Chile-based VidaCell Laboratories, Latin America’s oldest and largest cryopreserved umbilical cord cell bank. The alliance is focused on creating new protocols for cryopreservation of cord blood, cord tissue, adipose tissue and dental pulp stem cells, and the culture and expansion of cell colonies.

The GSCG / VidaCel alliance will provide both companies broader access to the newest stem cell technologies for application in new territories. With Global Stem Cells Group’s growing presence in Latin America, the collaboration with VidaCel will eliminate the potential for significant delays in collecting and processing stem cells, which can result in a loss of cell viability.

According to Global Stem Cells Group CEO Benito Novas, the rules of the National Program for Bone Marrow Donation in the U.S. provide the guidelines used by VidaCel for processing cord blood cells within 24 hours.

“VidaCel’s location in Chile guarantees immediate availability of cells,” Novas says.
“Their process of collecting, processing and preserving stem cells is performed under the strictest standards of biosecurity, and designed to better safeguard the material over a lifetime, which makes them a perfect collaborator for Global Stem Cells Group.”

Tissue stem cells, or mesenchymal stem cells, harvested from umbilical cord blood and tissue, can differentiate and generate cells of different tissues, mainly connective or supportive, such as bone, cartilage or muscle. Studies show that they can also participate in the process of tissue regeneration through other mechanisms such as immunosuppression, production factors and cell stimulators present in tissue or a damaged organ. Tissue stem cells also have characteristics that allow them to adapt fairly easily to the action of the immune system of an individual, which is why they are essential for use in allogeneic procedures in which immunologic compatibility is a factor.

Stem cells harvested from adipose tissue can differentiate into bone, cartilage, tendon and muscle, and can strengthen defensive and regenerative function. Adipose stem cells are found in adipose (fat) tissue.
Stem cells harvested from dental pulp can also differentiate into bone, cartilage, tendon and muscle to reinforce their defensive and regenerative function. These cells are found in the teeth.

Over time, the body’s stem cells succumb to environmental insults, a common occurrence in the aging process. Cryopreserving stem cells from young patients at an early stage means preserving their maximum viability.
To learn more, visit the Global Stem Cells Group website, email bnovas(at)regenestem(dot)com, or call 305-224-1858.

About the Global Stem Cells Group:

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

Global Stem Cells Group’s corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCG’s six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.

About VidaCel:

Established in 2004,VidaCel® is the largest cell blood bank in Latin America, known for its cryopreservation of umbilical cord stem cells, adipose tissue stem cells and dental pulp stem cells. VidaCel follows the rules of the National Program for Bone Marrow Donation’s. U.S. entity, which also provides guidelines concerning Cord Blood Banks.

Located in Santiago, Chile, VidaCel is the first and only public access stem cell bank in Chile, and guarantees immediate availability of cells. VidaCel is committed to the advancement of new technologies and treatments, in conjunction with leading universities. VidaCel is accredited by the Ministry of Health and the Public Health Institute, and all processes are certified by the international quality standard ISO-9001.

Global Stem Cells Group will launch two new versions of its “Diplomat in Cell Therapy and Tissue Engineering” post-graduate program. The program will be offered in Chile in 2016

MIAMI (PRWEB) SEPTEMBER 29, 2015

Stem Cell Training, Inc., a division of the Global Stem Cells Group, has announced plans to launch two new editions of the post-graduate diploma program, “Diplomat in Cell Therapy and Tissue Engineering.” The first of its kind worldwide, the program is designed for physicians and qualified practitioners to bring stem cell therapies into the doctor’s office to treat patients.

The program focuses on advances in cell biology that emerged in the late 20th and early 21st centuries to give rise to stem cell therapies—a new form of medical treatment in which cells and tissues are used as healing elements, not only to supplement or replace deficient cells, but to induce regeneration and restoration of a lost biological order during the development of a disease or injury.

According to Global Stem Cells Group CEO Benito Novas, cell therapy is becoming the foundation of future medicine. For that reason, making stem cell sciences and treatment courses available to physicians and qualified medical practitioners is fundamental to the future of medicine. “Diplomat in Cell Therapy and Tissue Engineering” offers professionals invaluable lessons in the new art of healing, as well as the scientific and practical methodologies concerning this new discipline.

The aim of this postgraduate course is to train high-achieving, academic level professionals in cell therapy and tissue engineering to use in different areas of medicine and dentistry.

Course topics include:

• Somatic cell therapy and tissue engineering and associated bioethical issues.
• Cell Structure and functions, cell and tissue growth, cell differentiation and genetic and epigenetic regulation.
• Interaction of cells with other cells and extracellular matrix, humeral microenvironment.
• Development of cell interactions during embryogenesis, tissue regeneration, tissue repair and cancer.
• Immunology: Humeral and cellular immunity, innate and acquired immunity, interactions, effector function, immune tolerance, trophic and reconstructive function.
• Biology of embryo development, and normal and pathological tissue repair: overview of embryonic and fetal post-natal development, genetic and epigenetic factors that influence growth, embryonic fetal and postnatal development, maintenance and repair process of cells, tissue and organs, and genetic and epigenetic factors that interact and influence these processes.
• Identification of certain cellular therapies that repair or correct defects.
• Method of production, processing and application of biological drugs for Cell Therapy and Tissue Engineering.
• Sources of the cells used in cell therapy. Enforcement of cell techniques. Complex manipulation processes, GMP Standards. Cell processing laboratories. The Biosafety and quality of cellular products: Identity, Purity, Power, Security.
• Cell administration. Implant techniques. Evaluating the results of cell therapy.
• Layout of clinical trials.

Educational strategies will be taught in theory and in practical hands-on classes, during which students can raise questions and work on problem solving. Practical work will be first carried out on animals; laboratory practices will be taught, followed by demonstration of therapies on humans.

Students will take a written exam on the last day; A score of 7 or better out of 10 is required to pass. Evaluations will be complemented with the development of a thesis, to be graded as pass or fail and must be supported with an oral examination.

To learn more, visit the Stem Cells Training website, the Global Stem Cells Group website, email bnovas(at)regenestem(dot)com, or call 305-224-1858.

About the Global Stem Cells Group:

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

Global Stem Cells Group’s corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCG’s six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.

About Stem Cell Training, Inc.:

Stem Cell Training, Inc. is a multi-disciplinary company offering coursework and training in 35 cities worldwide. Coursework offered focuses on minimally invasive techniques for harvesting stem cells from adipose tissue, bone marrow and platelet-rich plasma. By equipping physicians with these techniques, the goal is to enable them to return to their practices, better able to apply these techniques in patient treatments.

The company’s training courses are designed to make the best use of stem cell technology available to treat various diseases in a manner that is accessible to everyone. Stem Cell Training, Inc.’s mission is to introduce the promising world of cellular medicine to everyone who can benefit from its application, and to provide high quality, effective and efficient training that complies with the highest medical standards to physicians worldwide.

MIAMI (PRWEB) NOVEMBER 30, 2015

Global Stem Cells Group today announced the opening of a new, Good Manufacturing Practice (GMP) 10000 in the Santiago Marriott. The Global Stem Cells Group GMP facility is equipped with the most advanced technologies available, and is operated by a world-class team of qualified medical researchers and practitioners, experienced in administering stem cell protocols using highly manipulated cells.

GMPs are critical for cell therapy success. Understanding and incorporating GMP standards in clinical and pre-clinical research settings establishes a solid foundation on which to build clinical trials and to ensure the safety of biologic products. Good manufacturing practices ensure the safety and efficiency of stem cell products and the patients who receive them. The fundamentals of GMCs are also becoming an important part of the training received by academic researchers in the biotechnology industry, who are at the forefront of developing products for eventual clinical use.

The Global Stem Cells Group GMP 1000 facility will begin receiving international patients in early January 2016.

The GSCG therapeutic center in Santiago—a separate facility from the CMP 1000—will begin seeing international patients as of Dec. 1, 2015 to make its stem cell therapies and facilities available to international patients as well.

For more information, visit the Global Stem Cells Group website, Email bnovas(at)stemcellsgroup(dot)com, or call 305-560-5337.

About the Global Stem Cells Group:

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions.

With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

Global Stem Cells Groups corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCGs six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.

###

Miami-based Global Stem Calls Group has opened a state-of-the-art GMP facility in the Santiago Mariott. The facility will begin receiving international patients in January, 2016

MIAMI (PRWEB) NOVEMBER 30, 2015

Global Stem Cells Group today announced the opening of a new, Good Manufacturing Practice (GMP) 10000 in the Santiago Marriott. The Global Stem Cells Group GMP facility is equipped with the most advanced technologies available, and is operated by a world-class team of qualified medical researchers and practitioners, experienced in administering stem cell protocols using highly manipulated cells.

GMPs are critical for cell therapy success. Understanding and incorporating GMP standards in clinical and pre-clinical research settings establishes a solid foundation on which to build clinical trials and to ensure the safety of biologic products. Good manufacturing practices ensure the safety and efficiency of stem cell products and the patients who receive them. The fundamentals of GMCs are also becoming an important part of the training received by academic researchers in the biotechnology industry, who are at the forefront of developing products for eventual clinical use.

The Global Stem Cells Group GMP 1000 facility will begin receiving international patients in early January 2016.

The GSCG therapeutic center in Santiago—a separate facility from the CMP 1000—will begin seeing international patients as of Dec. 1, 2015 to make its stem cell therapies and facilities available to international patients as well.

For more information, visit the Global Stem Cells Group website, Email bnovas(at)stemcellsgroup(dot)com, or call 305-560-5337.

About the Global Stem Cells Group:

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions.

With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

Global Stem Cells Groups corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCGs six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.

###

Global Stem Cells Group Chile CEO Enrique Testart will represent the biotech company at the in First CIMECA Convention in Panama City Feb. 17-19, 2016

MIAMI (PRWEB) NOVEMBER 30, 2015

Global Stem Cells Group Chile CEO Eugene Testart, M.D., will join physicians, aesthetic practitioners and aesthetics professionals from Central America and abroad for the first Iberoamerican Convention on Aesthetic Medicine, Cosmetology and Anti-Aging (CIMECA), to be held in Panama City, Panama Feb. 17-19, 2016. Testart will present and discuss new trends in anti-aging stem cell treatments, regenerative medicine and applications in aesthetic medicine.

Global Stem Cells Group subsidiary https://stemcellsgroup.cl/sct will also implement a post-convention training certification course in stem cell techniques and technologies for physicians. The intensive, hands-on course in stem cell harvesting, isolation and re-integration, administered by by accredited and experienced specialists, and participants will receive detailed written protocols and a high-definition video of the procedure. Following course completion, each physician will receive certified stem cell specialist certification with with international validation for in-office stem cell procedures.

CIMECA will be the first event of its kind to be held in the Central America and Caribbean region to include medical and aesthetic professionals, businesses, and the Latin American public. The conference is designed to address the latest advances in aesthetic medicine, cosmetology, and anti-aging procedures from different perspectives.

The convention will feature keynote speeches, panel discussions and presentations on the latest trends, technologies and tools available to promote safe, profitable and ethical medical practices, together with the celebration of the first Aesthetic & Wellness Expo where the general public can participate.

CIMECA will address a wide variety of issues and treatments, including obesity, localized adiposity (the accumulation of fat tissue), cellulite, facial and body aesthetics, skincare. Keynote speeches and panel discussions will be accompanied by clinical case studies, new research in the field of aesthetics, new ideas, products and technologies that offer the latest developments and trends in aesthetic sciences.

CIMECA emerged on the initiative of a group of medical graduates of the Faculty of Medicine at the University of Panama and extension specialists in anti-aging medicine from the John F. Kennedy Argentine University and the Pinto Institute in Buenos Aires.

For more information, visit the Global Stem Cells Group website, email bnovas(at)stemcellsgroup(dot)com, or call 305-560-5337.

About the Global Stem Cells Group:

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions.

With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

Global Stem Cells Groups corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCGs six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.

About CIMECA:

The first IIberoamerican Convention on Antiaging and Aesthetic Medicine Cosmetology (CIMECA), to be held Feb. 17-19 2016, is a unique event that will bring together physicians, medical practitioners, businesses beauty professionals and the public from Panama and throughout Central America. Participants will engage in conferences, keynote speeches, panel discussions and presentations on the latest trends, technologies and tools available to promote safe, profitable and ethical aesthetic medical practices.

Global Stem Cells Group announces the appointment of Kipp Van Camp, D.O., Chief Operating Officer. Van Camp, a former family practitioner and interventional radiologist, was a GSCG advisory board member for years

MIAMI (PRWEB) DECEMBER 08, 2015

Global Stem Cells Group has announced the appointment of Kipp Van Camp, D.O. to the position of Chief Operating Officer for the international biotech company. Van Kamp is an interventional radiologist and former family practitioner with a medical career spanning 25 years.

According to Global Stem Cells Group CEO Benito Novas, Van Camp’ distinct background in medicine, entrepreneurial ventures and corporate management makes him the obvious choice to spearhead a new era of growth for the company.

As COO, Van Camp will take over direct management of GSCG’s day-to-day operations, and make managerial decisions.

Van Camp is the author of “Misdiagnosis: A Practicing Physician’s Case Study of Health Care Reform,” and hosts the popular “Doctor’s Orders” radio show. A native of western Kansas, he is triple board certified in family medicine and radiology, Van Camp co-owns radiology practices in Kansas City and Topeka, Kansas, and is the owner and Medical Director of Rejuvenate Medical Spa in Topeka, where he administers minimally invasive cosmetic treatments.

He serves as an adjunct professor at Washburn University and the University of Kansas. He also engages in clinical and scientific medical research, and serves as the Medical Director of Precise Clinical Research.

For four years, Van Camp served as a member of the Global Stem Cells Group advisory board, and is well acquainted with the company’s mission to bring the latest stem cell therapies to patients worldwide.

“We are very happy to have an esteemed professional like Dr. Van Camp to fill the position of Global Stem Cells Group’s chief operating officer,” Novas says. “He possesses the knowledge, experience, and commitment to the potential of stem cell technology that is necessary to fill this position, which makes him a critical addition to the team, one who will ensure we are well positioned into the future.”

To learn more, visit the Global Stem Cells Group website, Email bnovas@stemcellsgroup.com, or call 305-560-5337.

About the Global Stem Cells Group:

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions.
With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

Global Stem Cells Groups corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCGs six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.

About Kipp Van Camp, D.O.

An interventional radiologist and former family practitioner, Kipp Van Camp, D.O. (“Dr. Kipp”) is triple board certified in family medicine and radiology. A native of western Kansas, he earned a doctor of osteopathic medicine degree (D.O.) from Kansas City University of Medicine and Biosciences in 1990.

Van Camp is the author of “Misdiagnosis: A Practicing Physician’s Case Study of Health Care Reform,” and hosts the popular“Doctor’s Orders” radio show. He served on the Global Stem Cells Group advisory board for four years.

His formal education includes medical training with two residencies and a fellowship covering a span of nine years of post-graduate education. He began his medical career practicing family medicine in rural northwest Missouri, performing a variety of duties, including delivering babies, pediatrics and elder care. After completing his residency in diagnostic radiology at Oklahoma State University in Tulsa, Van Camp received a fellowship in interventional radiology at Washington Hospital Center in Washington, DC.

His passion for medicine and an entrepreneurial spirit led him to pursue and establish a variety of health-centric ventures. He co-owned radiology practices in Kansas City, Missouri and Topeka, Kansas, and was owner and medical director of Rejuvenate Medical Spa in Topeka, where he administered minimally invasive cosmetic medical treatments.

Van Camp is an adjunct professor at Washburn University and the University of Kansas, and participates in clinical and scientific medical research. He serves as the Medical Director of Precise Clinical Research.

Global Stem Cells Group has announced the opening of two new stem cell centers in the cities of Arica and Iquique in northern Chile. The new centers are the latest part of Global Stem Cells Groups’ expansion efforts in Latin America.

MIAMI (PRWEB) NOVEMBER 30, 2015

Global Stem Cells Group announced the opening of a new core patient care hub with the opening of two new clinics in the cities of Arica and Iquique in northern Chile. The facilities are part of GSCG’s expansion efforts in Latin America.

Both the Arica and Iquique clinics offer the most advanced protocols and techniques in stem cell medicine to patients from around the world.

The clinics will be headed by Victor Perez, M.D. and Duval Aguirre, M.D.

Global Stem Cells Group, is expanding its clinical presence throughout Latin America and worldwide by partnering with qualified physicians experienced in stem cell therapies to open new clinics. The new Arica and Iquique clinics are certified for the medical tourism market.

GSCG is committed to the highest standards in service and technology, expert and compassionate care, and a philosophy of exceeding the expectations of their international patients.

For more information, visit the Global Stem Cells Group website, Email bnovas(at)stemcellsgroup(dot)com, or call 305-560-5337.

About the Global Stem Cells Group:

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions.
With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

Global Stem Cells Groups corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCGs six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.

MIAMI, Nov. 24, 2015—GlobalStemCellsGroup has announced plans to participate in the 2t6h annual Argentine Congress of Aesthetic Medicine March 31-April 2, 2016 in Buenos Aires. Physicians and stem cell experts from the U.S. and Argentina will be present to share new findings in regenerative and aesthetic medicine.
Following the symposium, Global Stem Cells Group will conduct an intensive, hands-on course in stem cell harvesting, isolation and re-integration for physicians and qualified medical practitioners who wish to offer stem cell treatments to patients in their office.
Hosted by the pioneering Argentina Society of Aesthetic Medicine (SOARME) in conjunction with the Pinto Institute, the conference will feature acclaimed stem cell aesthetic practitioners from Argentina and the U.S. As a member of the Argentine Medical Association (A.M.A.) and of the International Union of Aesthetic Medicine (U.I.M.E.). SOARME has the scientific support of the John F. Kennedy Argentine University in Buenos Aires, and a host of national and international scientific organizations.
Pinto Institute President Raul Pinto says the symposium will feature the latest therapeutic approaches to aesthetic pathologies, ranging from clinical trials to minimally invasive procedures with low risk to patients.
“This will be the fourth year Global Stem Cells Group participates in the conference, and we’re looking forward to Raul Pinto and the Pinto Institute’s contributions,” says Global Stem Cell Group CEO Benito Novas. “Regenerative aesthetic medicine is one of the fastest growing fields in stem cell applications, and Dr. Pinto and the Pinto Institute has pioneered teaching aesthetic medicine and anti-aging procedures to physicians in Argentina.”
The conference will be held at the Catholic University of Argentina in Buenos Aires.
For more information visit the Global Stem Cells Group website, email bnovas(at)regenestem(dot)com, or call 305-224-1858.
About the Global Stem Cells Group:
Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions.
With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.
Global Stem Cells Group’s corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCG’s six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.
About the Argentina Society of Aesthetic Medicine (SOARME):
Pioneered by Raul Pinto, the Argentina Society of Aesthetic Medicine (SOARME) was accepted into Argentina’s Union Internationale de Medecine Esthetique (UMIE) in 1993, 13 years after Raul Pinto, M.D. became the first physician to bring aesthetic medicine to the Americas. Since then, SOARME has promoted collaboration with aesthetic and plastic surgeons, and worked to improve its safety and efficiency so that aesthetic surgery minimizes the possible risks to patients.
According to SOARME, the objectives of aesthetic medicine include the maintenance, promotion and restoration of aesthetics, beauty and health, for which it uses non-invasive and minimally invasive procedures in clinical practice, and in which topical or local anesthesia is used in an out-patient system. SOARME member countries include France, Italy, Belgium, Spain, Morocco, Uraguay, Argentina, Brazil, Switzerland, Poland, Colombia, Venezuela, Chile, U.S.A., Mexico, Russia, Kazakhstan, Algeria, Canada, Korea, Turkey, South Africa, Ecuador, China, Ukraine and Georgia.
About Raul Pinto, M.D. and the Pinto Institute:
The Pinto Institute, the first school of aesthetic medicine founded in the Americas, began its educational activity in aesthetic medicine and related specialties in 1991 in the Palermo district of Buenos Aires, as the Academic Medical Center Department of the Pinto Institute, and with the support of the Argentina Society of Aesthetic Medicine (SOARME).
In1992, the John F. Kennedy Argentine University provided scientific support and began with the first university training in aesthetic medicine. In 1996, founder Raul Pinto, M.D. issued the first  diploma in aesthetic medicine in the Americas, with international corporate support of the Pan-American Society of Aesthetic Medicine (PASAM) and the Union Internationale de Medecine Esthetique  (UIME) School in Buenos Aires. In 2002, Pinto Institute received the first accreditation in anti-aging medicine, sponsored by the Aesthetic & Anti-Aging Medicine International Society (AAAMISO)  and the European Society of Anti-Aging Medicine (ESAAM).
Pinto Institute offers courses related to aesthetic medicine specialties with accreditation guarantees from the European Applicazioni Società Biomediche (SEAB) and Hispanic American College of Physicians & Surgeons in Miami.
Since 2009, courses have been held in conjunction with the John F. Kennedy Argentine University. In 2010 the school moved to the Puerto Madero neighborhood of Buenos Aires and was renamed Pinto Institute of Teaching and Research in Aesthetic Medicine, freeing up physical space for SOARME to expand development of its scientific activities.
Since 2010, SOARME has directed and  trained students in aesthetic medicine in conjunction with the Medical Association Argentina (AMA) at the Pinto Institute.
###